Ready to play
Ready to play
A recent blood test used for early cancer detection, designed by Grail, faces a major regulatory hurdle in the United States. This test searches for multiple types of cancer by detecting tumor DNA fragments, aiming to identify cancers at early stages, making treatment easier compared to traditional methods like mammography or colonoscopy, which screen for just one type of cancer per test. Today, Wednesday, FDA advisors will evaluate the effectiveness of this test, especially regarding its ability to detect cancers early. The agency has not raised significant safety concerns but is interested in discussing how well the test can identify cancers at an early stage before approving it for market.
Notice: This Is an AI-Generated Summary
Comments (0)